ABIVAX SA SP.ADR EO -,01

ABIVAX SA SP.ADR EO -,01

Depository Receipt · US00370M1036 · ABVX · A3EWCP (XNMS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ABIVAX SA SP.ADR EO -,01
No Price
29.04.2026 08:20
Current Prices from ABIVAX SA SP.ADR EO -,01
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ABVX
USD
29.04.2026 08:20
109,50 USD
-0,37 USD
-0,34 %
XDQU: Quotrix
Quotrix
ASAAPS36.DUSD
EUR
29.04.2026 07:12
94,00 EUR
-3,50 EUR
-3,59 %
XHAM: Hamburg
Hamburg
ASAAPS36.HAMB
EUR
29.04.2026 06:11
93,50 EUR
-4,00 EUR
-4,10 %
IEXG: IEX
IEX
ABVX
USD
28.04.2026 19:59
109,96 USD
-1,94 USD
-1,73 %
XDUS: Düsseldorf
Düsseldorf
ASAAPS36.DUSB
EUR
28.04.2026 06:12
95,00 EUR
-2,50 EUR
-2,56 %
Company Profile for ABIVAX SA SP.ADR EO -,01 Depository Receipt
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Company Data

Name ABIVAX SA SP.ADR EO -,01
Company Abivax S.A.
Symbol ABVX
Website https://www.abivax.com
Primary Exchange XNMS Frankfurt
WKN A3EWCP
ISIN US00370M1036
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Marc M. P. de Garidel
Market Capitalization 7 Mrd.
Country France
Currency EUR
Employees 0,1 T
Address 5, rue de la Baume, 75008 Paris
IPO Date 2023-10-20

Ticker Symbols

Name Symbol
Düsseldorf ASAAPS36.DUSB
Frankfurt 2X10.F
Hamburg ASAAPS36.HAMB
NASDAQ ABVX
Quotrix ASAAPS36.DUSD
More Shares
Investors who hold ABIVAX SA SP.ADR EO -,01 also have the following shares in their portfolio:
SUESS MICROTEC SE
SUESS MICROTEC SE Share
TRISTATE CAPITAL HOLDINGS INC- DEP SHS REP 1/40TH INT 6.75% SRS A NON-CUM PFD
TRISTATE CAPITAL HOLDINGS INC- DEP SHS REP 1/40TH INT 6.75% SRS A NON-CUM PFD Share